Weight management · Phase 2
Subcutaneous amycretin: early human study
What was tested?
Subcutaneous amycretin versus placebo across several cohorts with different treatment durations. ↗
Registered primary question: The number of treatment-emergent adverse events, assessed through the end of each study part. ↗
What the reviewed report found
Journal year 2025 · Article summary reviewed 2026-09-15
Estimated weight reductions were greater with amycretin. Gastrointestinal events were common, and the authors reported many study withdrawals.↗
Keep in context: Weight findings came from small cohorts followed for different lengths of time. The authors reported substantial withdrawal, which limits interpretation of the estimates. ↗↗
Participants, design, limitations and sources
Registry snapshot
- Registry enrollment
- 125 · reported actual
- Registry status
- Completed
- Allocation and masking
- Randomized · Quadruple
- Design
- Parallel
- Eligible ages
- 18 Years to 55 Years
- Registry results
- Not posted in this snapshot
Registry source ↗ · Updated 2025-11-19; retrieved 2026-09-20. Registry enrollment is not necessarily the analyzed sample in a publication. Posted registry results and published article results are separate.
Subcutaneous amycretin: phase 1b/2a study
- Design in the report
- A randomized placebo-controlled multipart study assessed safety and secondary body-weight changes over up to 36 weeks.↗
- Participants in the report
- The study randomized 125 adults with overweight or obesity at one research center.↗
- Limitations
- Primary endpoints concerned adverse events. Small cohorts, different observation lengths and substantial attrition limit comparisons and interpretation of weight estimates.↗
This reading covers the article abstract and record metadata. Read its preserved Human Evidence Review →
How the study identity and sources were checked
Study context checked 2026-09-20. Existing article summaries keep their original review dates. This is a selected study reading, not a complete literature or full-text appraisal.
Registry
A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin ↗
Protocol identifier: NN9490-7613. Sponsor: Novo Nordisk A/S.
Retrieved 2026-09-20; SHA-256 07b607555cf7f16ab5bfedbe4a491fd148e8c233c5bc46f36ba9be330e301658.
PMID 40550231
Exact trial identity is declared in PubMed’s ClinicalTrials.gov databank field. The registry independently labels this reference DERIVED. These source labels do not establish that every result in a paper applies to this trial.
Identity metadata retrieved 2026-09-20. EFetch batch XML; locate MedlineCitation/PMID 40550231. SHA-256 adc8edd8b150d99a3641ddbc74c59db6916cf35d9d6246838aaff2cc195ae1cb.
Scientific summary uses the original 2026-09-15 source snapshot: SHA-256 e7375cc3b76d64492e736999fb294aa940d3a369b35d3e0f5fc7c59514bf5c80.